{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:28:27Z","timestamp":1787588907218,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"am","delay-in-days":283,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.josat.2024.209431","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T13:44:57Z","timestamp":1717767897000},"page":"209431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Provision of medications to treat opioid use disorder via a mobile health unit: A scoping review"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9006-6262","authenticated-orcid":false,"given":"Amelia","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"DaCunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siena C.","family":"Napoleon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine W.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Kemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209431_bb7000","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ijmr.12102","article-title":"Shades of Grey: Guidelines for work- ing with the Grey literature in systematic reviews for management and organizational studies","volume":"19","author":"Adams","year":"2017","journal-title":"International Journal of Management Reviews"},{"key":"10.1016\/j.josat.2024.209431_bb0005","series-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2023"},{"issue":"4","key":"10.1016\/j.josat.2024.209431_bb0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/pubmed\/fdi056","article-title":"It\u2019s in your hands: The value of handsearching in conducting systematic reviews of public health interventions","volume":"27","author":"Armstrong","year":"2005","journal-title":"Journal of Public Health (Oxford, England)"},{"issue":"10182","key":"10.1016\/j.josat.2024.209431_bb0015","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: Present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.josat.2024.209431_bb0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2018.08.007","article-title":"Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years","volume":"836","author":"Blanco-Gand\u00eda","year":"2018","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.josat.2024.209431_bb0025","article-title":"Mobile narcotic treatment programs: On the road again?","volume":"14","author":"Breve","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.josat.2024.209431_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108483","article-title":"Mobile methadone medication units: A brief history, scoping review and research opportunity","volume":"129","author":"Chan","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.josat.2024.209431_bb0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/00952990802647495","article-title":"Residential treatment modifications: Adjunctive services to accommodate clients on methadone","volume":"35","author":"Chen","year":"2009","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.josat.2024.209431_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104141","article-title":"Typology of laws restricting access to methadone treatment in the United States: A latent class analysis","volume":"119","author":"Conway","year":"2023","journal-title":"The International Journal on Drug Policy"},{"issue":"12","key":"10.1016\/j.josat.2024.209431_bb0045","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.josat.2024.209431_bb0050","series-title":"The new Mobile methadone rules and what they mean for treatment access","author":"El-Sabawi","year":"2021"},{"key":"10.1016\/j.josat.2024.209431_bb0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.drugalcdep.2018.05.033","article-title":"Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients","volume":"192","author":"Gaither","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.josat.2024.209431_bb0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1353\/hpu.2017.0065","article-title":"Innovative program delivery and determinants of frequent visitation to a Mobile medical Clinic in an Urban Setting","volume":"28","author":"Gibson","year":"2017","journal-title":"Journal of Health Care for the Poor and Underserved"},{"key":"10.1016\/j.josat.2024.209431_bb0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cct.2016.12.015","article-title":"Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment","volume":"53","author":"Gordon","year":"2017","journal-title":"Contemporary Clinical Trials"},{"issue":"2","key":"10.1016\/j.josat.2024.209431_bb0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0376-8716(96)01273-2","article-title":"Patient retention in mobile and fixed-site methadone maintenance treatment","volume":"42","author":"Greenfield","year":"1996","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0075","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/07853890.2021.2022188","article-title":"Awareness, perception and utilization of a mobile health clinic by people who use drugs","volume":"54","author":"Grieb","year":"2022","journal-title":"Annals of Medicine"},{"issue":"4","key":"10.1016\/j.josat.2024.209431_bb0080","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jsat.2013.11.002","article-title":"Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals","volume":"46","author":"Hall","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0085","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1186\/s12913-019-4751-4","article-title":"Opioid use disorder and treatment: Challenges and opportunities","volume":"19","author":"Hoffman","year":"2019","journal-title":"BMC Health Services Research"},{"key":"10.1016\/j.josat.2024.209431_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108927","article-title":"Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use","volume":"227","author":"Hollander","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.josat.2024.209431_bb0100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/ajad.13055","article-title":"Mobile, community-based buprenorphine treatment for veterans experiencing homelessness with opioid use disorder: A pilot","volume":"29","author":"Iheanacho","year":"2020","journal-title":"Feasibility Study. Am J Addict"},{"issue":"3","key":"10.1016\/j.josat.2024.209431_bb0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/014107680309600304","article-title":"Five steps to conducting a systematic review","volume":"96","author":"Khan","year":"2003","journal-title":"Journal of the Royal Society of Medicine"},{"key":"10.1016\/j.josat.2024.209431_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap","volume":"103","author":"Krawczyk","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209431_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108329","article-title":"Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings","volume":"126","author":"Krawczyk","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0740-5472(02)00343-4","article-title":"Feasibility of referring drug users from a needle exchange program into an addiction treatment program: Experience with a mobile treatment van and LAAM maintenance","volume":"24","author":"Kuo","year":"2003","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.josat.2024.209431_bb0125","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.josat.2024.209431_bb0130","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/hep.26387","article-title":"Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis","volume":"58","author":"Larney","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.josat.2024.209431_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsat.2018.08.009","article-title":"Factors associated with methadone maintenance therapy discontinuation among people who inject drugs","volume":"94","author":"Lo","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12939-020-1135-7","article-title":"Mobile health clinics in the United States","volume":"19","author":"Malone","year":"2020","journal-title":"International Journal for Equity in Health"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.15288\/jsad.2014.75.179","article-title":"Intersecting identities and substance use problems: Sexual orientation, gender, race, and lifetime substance use problems","volume":"75","author":"Mereish","year":"2014","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0150","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0155","first-page":"16","article-title":"Challenges and opportunities to meet the mental health needs of underserved and disenfranchised populations in the United States","volume":"18","author":"Mongelli","year":"2020","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"5","key":"10.1016\/j.josat.2024.209431_bb0160","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1017\/cts.2020.42","article-title":"A call to action to address rural mental health disparities","volume":"4","author":"Morales","year":"2020","journal-title":"Journal of Clinical and Translational Science"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13722-020-00188-5","article-title":"Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): Protocol for an evaluation of two randomized effectiveness trials","volume":"15","author":"Murphy","year":"2020","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2024.209431_bb0175","article-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences, E., & Medicine","year":"2019","journal-title":"The National Academies Press."},{"key":"10.1016\/j.josat.2024.209431_bb0180","article-title":"Expanding buprenorphine treatment to people experiencing homelessness through a mobile, multidisciplinary program in an urban, underserved setting","volume":"127","author":"O\u2019Gurek","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209431_bb0185","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fpubh.2020.00501","article-title":"Community Care in Reach: Mobilizing harm reduction and addiction treatment Services for Vulnerable Populations","volume":"8","author":"Regis","year":"2020","journal-title":"Frontiers in Public Health"},{"key":"10.1016\/j.josat.2024.209431_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108553","article-title":"Mobile low-threshold buprenorphine integrated with infectious disease services","volume":"133","author":"Rosecrans","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","article-title":"Geographic and specialty distribution of US physicians trained to treat opioid use disorder","volume":"13","author":"Rosenblatt","year":"2015","journal-title":"Annals of Family Medicine"},{"issue":"4","key":"10.1016\/j.josat.2024.209431_bb0200","article-title":"The EMERALD (enabling mobilization, empowerment, risk reduction, and lasting dignity) study: Protocol for the design, implementation, and evaluation of a community-based combination HIV prevention intervention for female sex Workers in Baltimore","volume":"10","author":"Silberzahn","year":"2021","journal-title":"Maryland. JMIR Res Protoc"},{"issue":"4","key":"10.1016\/j.josat.2024.209431_bb0205","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/08897077.2020.1846149","article-title":"System-level factors shaping the implementation of \u201chub and spoke\u201d systems to expand MOUD in rural areas","volume":"42","author":"Snell-Rood","year":"2021","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2024.209431_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108377","article-title":"Transporting to treatment: Evaluating the effectiveness of a mobile engagement unit","volume":"129","author":"Stewart","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.josat.2024.209431_bb0215","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2215-0366(20)30538-1","article-title":"Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: A three-setting analysis","volume":"8","author":"Stone","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1016\/j.josat.2024.209431_bb0220","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.josat.2024.209431_bb0225","series-title":"Covidence systematic review software","author":"Veritas Health Innovation","year":"2023"},{"issue":"2","key":"10.1016\/j.josat.2024.209431_bb0230","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.josat.2024.209431_bb0235","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1213\/ANE.0000000000002496","article-title":"Risk factors for opioid-use disorder and overdose","volume":"125","author":"Webster","year":"2017","journal-title":"Anesthesia and Analgesia"},{"issue":"8","key":"10.1016\/j.josat.2024.209431_bb0240","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18487","article-title":"Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder","volume":"4","author":"Weintraub","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209431_bb0245","author":"Yale Program in Addiction Medicine"},{"issue":"1","key":"10.1016\/j.josat.2024.209431_bb0250","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12939-017-0671-2","article-title":"The scope and impact of mobile health clinics in the United States: A literature review","volume":"16","author":"Yu","year":"2017","journal-title":"International Journal for Equity in Health"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924001437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875924001437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T19:31:38Z","timestamp":1728588698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875924001437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":51,"alternative-id":["S2949875924001437"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209431","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Provision of medications to treat opioid use disorder via a mobile health unit: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"209431"}}